ARTICLE | Company News
Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) expanded a 2015 immuno-oncology deal to increase and accelerate investment in the clinical development of anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) for cancer and Dupixent dupilumab (REGN668, SAR231893) for allergic diseases.
In 2015, the partners entered a five-year deal to jointly develop and commercialize immuno-oncology candidates including cemiplimab and a pipeline of preclinical monoclonal and bi-specific antibodies. Under the original deal, each company would commit $325 million to develop cemiplimab (see BioCentury, Aug. 3, 2015)...